650 related articles for article (PubMed ID: 33478838)
1. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
[TBL] [Abstract][Full Text] [Related]
3. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
[TBL] [Abstract][Full Text] [Related]
5. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806).
Isfahanian N; Lukka H; Dayes I; Quan K; Schnarr KL; Douvi G; Goldberg M; Wright J; Swaminath A; Chow T; Diamond K; Cutz JC; Kavsak P; Thabane L; Tsakiridis T
Clin Genitourin Cancer; 2020 Aug; 18(4):e410-e415. PubMed ID: 32265129
[TBL] [Abstract][Full Text] [Related]
7. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
[TBL] [Abstract][Full Text] [Related]
8. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
[TBL] [Abstract][Full Text] [Related]
9. Dramatically Polarized Opinion on the Role of Brachytherapy Boost in Management of High-risk Prostate Cancer: A Survey of North American Genitourinary Expert Radiation Oncologists.
McClelland S; Sandler KA; Degnin C; Chen Y; Mitin T
Clin Genitourin Cancer; 2018 Jun; 16(3):e543-e545. PubMed ID: 29452837
[TBL] [Abstract][Full Text] [Related]
10. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
[TBL] [Abstract][Full Text] [Related]
12. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
13. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.
Fischer-Valuck BW; Rao YJ; Brenneman RJ; Patel PR; Filson CP; Jani AB; Liu Y; Goyal S; Xu K; Weiss A; Kucuk O; Cimmino C; Szabo S; Rossi P; Baumann BC; Pattaras J; Hershatter B; Patel SA
Brachytherapy; 2020; 19(5):557-566. PubMed ID: 32624405
[TBL] [Abstract][Full Text] [Related]
14. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
[TBL] [Abstract][Full Text] [Related]
16. Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer.
Andruska N; Michalski JM; Carmona R; Agabalogun T; Brenneman RJ; Gay HA; Fischer-Valuck BW; Baumann BC
Brachytherapy; 2022; 21(3):317-324. PubMed ID: 35123889
[TBL] [Abstract][Full Text] [Related]
17. Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy.
Schiffmann J; Lesmana H; Tennstedt P; Beyer B; Boehm K; Platz V; Tilki D; Salomon G; Petersen C; Krüll A; Graefen M; Schwarz R
Strahlenther Onkol; 2015 Apr; 191(4):330-7. PubMed ID: 25471276
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer.
Patel SA; Switchenko JM; Fischer-Valuck B; Zhang C; Rose BS; Chen RC; Jani AB; Royce TJ
Radiat Oncol; 2020 Sep; 15(1):217. PubMed ID: 32933541
[TBL] [Abstract][Full Text] [Related]
19. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.
Kishan AU; Steigler A; Denham JW; Zapatero A; Guerrero A; Joseph D; Maldonado X; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Tilki D; Karnes RJ; Tosoian JJ; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Jiang T; Ma TM; Xiang M; Philipson R; Chang A; Kupelian PA; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Boutros PC; Horwitz EM; Tendulkar RD; Spratt DE; Romero T
JAMA Oncol; 2022 Mar; 8(3):e216871. PubMed ID: 35050303
[TBL] [Abstract][Full Text] [Related]
20. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.
Jackson WC; Hartman HE; Dess RT; Birer SR; Soni PD; Hearn JWD; Reichert ZR; Kishan AU; Mahal BA; Zumsteg ZS; Efstathiou JA; Kaffenberger S; Morgan TM; Mehra R; Showalter TN; Krauss DA; Nguyen PL; Schipper MJ; Feng FY; Sandler HM; Hoskin PJ; Roach M; Spratt DE
J Clin Oncol; 2020 Sep; 38(26):3024-3031. PubMed ID: 32396488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]